Atlas Trials

A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

Clinical trial NCT02608073 · COMPLETED

Trial details

NCT number
NCT02608073
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Nasopharyngeal Cancer
Start date
2004-11-01
Primary completion
2009-11-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.